The increasing prevalence of chronic diseases like diabetes, hypertension, and heart disease among younger populations in China has highlighted the need for effective treatments. Peony seed oil, rich in unsaturated fatty acids, particularly alpha-linolenic acid, shows significant hypoglycemic effects. When combined with soybean and rapeseed oils, these effects are enhanced [1].  This study evaluated the hypoglycemic properties of peony seed oil, soybean oil, rapeseed oil, and their blends through in vitro and in vivo experiments, network pharmacology, and molecular docking. GC-MS analysis identified nine major components, including γ-sitosterol, alpha-linolenic acid, linoleic acid, and palmitic acid [2]. The optimal ratio for α-amylase and α-glucosidase inhibition was determined as 60:27:11 (peony seed oil: soybean oil: rapeseed oil). Network pharmacology and molecular docking revealed linoleic acid and alpha-linolenic acid as key active compounds, with PPARG and MAPK3 as critical targets. The PPAR and IL17 signaling pathways play significant roles in the hypoglycemic action of the peony seed oil blend. In conclusion, the new peony seed blended oil offers a multi-component, multi-target, multi-pathway, and synergistic approach to diabetes treatment, providing valuable insights for the development of next-generation hypoglycemic drugs with practical applications [3][4].